Literature DB >> 25198885

Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors.

Andrea Trabocchi1, Nicolino Pala, Ilga Krimmelbein, Gloria Menchi, Antonio Guarna, Mario Sechi, Tobias Dreker, Andrea Scozzafava, Claudiu T Supuran, Fabrizio Carta.   

Abstract

The protein arginine deiminase 4 (PAD4) is a calcium-dependent enzyme, which catalyses the irreversible conversion of peptidyl-arginines into peptidyl-citrullines and plays an important role in several diseases such as in the rheumatoid arthritis, multiple sclerosis, Alzheimer's disease, Creutzfeldt-Jacob's disease and cancer. In this study, we report the inhibition profiles and computational docking toward the PAD4 enzyme of a series of 1,2,3-triazole peptidomimetic-based derivatives incorporating the β-phenylalanine and guanidine scaffolds. Several effective, low micromolar PAD4 inhibitors are reported in this study.

Entities:  

Keywords:  Arginine mimic; PAD4 inhibitors; cancer; peptidomimetic; rheumatoid arthritis

Mesh:

Substances:

Year:  2014        PMID: 25198885     DOI: 10.3109/14756366.2014.947976

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  3 in total

Review 1.  Peptidylarginine Deiminases-Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?

Authors:  Sigrun Lange; Mark Gallagher; Sharad Kholia; Uchini S Kosgodage; Mariya Hristova; John Hardy; Jameel M Inal
Journal:  Int J Mol Sci       Date:  2017-06-05       Impact factor: 5.923

Review 2.  Triazole-Modified Peptidomimetics: An Opportunity for Drug Discovery and Development.

Authors:  Agnieszka Staśkiewicz; Patrycja Ledwoń; Paolo Rovero; Anna Maria Papini; Rafal Latajka
Journal:  Front Chem       Date:  2021-05-20       Impact factor: 5.221

Review 3.  Peptidylarginine Deiminases as Drug Targets in Neonatal Hypoxic-Ischemic Encephalopathy.

Authors:  Sigrun Lange
Journal:  Front Neurol       Date:  2016-02-22       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.